Milestone for Arana
Thursday, 02 October, 2008
Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.
The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.
It was then further refined using the company's EvoGene optimisation technology.
Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.
Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
